Delfi Krishna, Ph.D.
Vice President Late-Stage Development
Delfi Krishna joined Immatics in January 2021 and is responsible for the late-stage development of cell therapies. She leads a cross-functional medicine development team to bring autologous cell therapies to market.
Delfi has nearly 20 years of experience contributing to 15 biologics and 11 different cell therapies from discovery to commercialization. During her Ph.D. at Georgia Institute of Technology, she designed efficient and targeted retroviral and lentiviral vectors for gene delivery in human cells.
After completing her postdoctoral research, Delfi joined GlaxoSmithKline, where she led large matrix teams to drive process development, product strategy and regulatory submissions for several monoclonal antibodies, domain antibodies and antibody drug conjugates. Delfi executed strategies to reduce costs, increase agility and shaped the technology, portfolio, organizational and talent strategy for the cell therapy business unit. Delfi Krishna recently completed her MBA from MIT Sloan School of Management. She strives to inspire colleagues to deliver innovative medicines to patients while fostering growth, confidence and promoting a fun boundary breaking environment.
Back
After completing her postdoctoral research, Delfi joined GlaxoSmithKline, where she led large matrix teams to drive process development, product strategy and regulatory submissions for several monoclonal antibodies, domain antibodies and antibody drug conjugates. Delfi executed strategies to reduce costs, increase agility and shaped the technology, portfolio, organizational and talent strategy for the cell therapy business unit. Delfi Krishna recently completed her MBA from MIT Sloan School of Management. She strives to inspire colleagues to deliver innovative medicines to patients while fostering growth, confidence and promoting a fun boundary breaking environment.